Keywords Latin America - demographics - hepatocellular carcinoma - risk factors
Hepatocellular carcinoma (HCC) accounts for 75 to 85% of all liver cancers, and carries
a high burden in terms of incidence and mortality worldwide. Cholangiocarcinoma represents
around 15%, and other subtypes of liver cancers are even rarer. Generally, global
statistics report data on liver cancer, without discriminating the histologic subtype.[1 ]
In 2016, there were over 1 million cases of liver cancer worldwide and 800,000 deaths.[1 ] From 1990 to 2016, the incidence of liver cancer increased by 114% with a standardized
incidence ratio of 0.34% per year in this period.[2 ] In the United States, liver cancer diagnosis increased at a higher rate than any
other malignancy in the past decade.[3 ] The World Health Organization estimates that more than 1 million patients will die
of this neoplasia in 2030.[4 ]
The incidence of liver cancer varies significantly across different regions because
of the varying prevalence of underlying risk factors. The highest incidence is observed
in East Asia with an age-standardized incidence rate of 34.1 per 100,000, followed
by Asia-Pacific (22.9 per 100,000), South-East Asia (11.8 per 100,000), and Central
sub-Saharan Africa (10.3 per 100,000). On the other hand, North America presents an
incidence of 7.1 per 100,000 and Western Europe 7.4 per 100,000.[2 ] Similarly, the age-standardized mortality rates are highest in Eastern Asia (16.0
per 100,000) followed by Northern Africa (13.9 per 100,000) and Eastern Asia (13.2
per 100,000).[5 ] Incidence and mortality are numerically close across different regions, which reflects
the high lethality of this neoplasia. Indeed, this is explained by the significant
proportion of patients with HCC who are diagnosed at advanced stage or will develop
disease recurrence after locoregional treatments.
The most frequent etiologies are chronic infection by hepatitis B (HBV) or C viruses
(HCV) and alcohol intake. Notably, an increasing trend in the prevalence of nonalcoholic
fatty liver disease (NAFLD) associated with an increasing prevalence of obesity, diabetes
mellitus, and metabolic syndrome is leading to changes in the geographic distribution
of HCC, mainly in Western countries.[6 ] This explains why a more pronounced increase in incidence is being observed in countries
with favorable sociodemographic indicators. On the contrary, chronic infection by
HBV is the main cause of HCC in high-prevalence countries such as China, while HCV
still represents the main cause of HCC in Japan, Europe, and North America.[7 ]
The implementation of effective antiviral therapy with the direct-acting antiviral
(DAA) drugs will potentially impact positively on reducing the global incidence of
HCV-related HCC, although some issues regarding the risk of recurrence after local
treatments are still being debated.[8 ] HBV vaccination has also been shown to significantly reduce the incidence of HCC,
demonstrating that mortality can be prevented by controlling and eradicating the causative
factors.[9 ] Taken together, these findings support the prediction that HCC epidemiology is shifting
from an infectious background to a disease primarily associated with fatty liver disease.
Having briefly contextualized the global landscape, we aim to describe the current
scenario and future trends of HCC in Latin America, focusing on the main risk factors,
surveillance, and particularities of HCC epidemiology in this region.
Latin America—Structural Challenges
Latin America—Structural Challenges
Latin America is composed of 20 countries, representing almost 13% of the Earth's
land surface area with an estimated population of more than 639 million. Latin America
presents cultural and demographic heterogeneity and also a remarkable wealth disparity.
Some Latin American countries account for the highest indicators of social and economic
inequality.[10 ] There are significant inequities between urban and rural areas, some of which are
remote and lack access to healthcare, even in primary needs. Countries that rank lower
in human development index,[11 ] such as Haiti, Honduras, Nicaragua, and Bolivia, suffer from lack of human and technology
resources, which explains the paucity of health data from many of them.
Many Latin American zones have experienced an intense urbanization process over the
last 50 years. Today, approximately 80% of the region's population lives in cities.
However, urbanization is high concentrated. Only Mexico and Brazil have more than
a dozen cities with over a million inhabitants, while Uruguay and Paraguay do not
have more than two cities with a population of more than a million. Despite the rates
of urbanization, ineffective urban planning models prevent the implementation of a
comprehensive health access in many urban centers. Even within urbanized areas, center-periphery
disparities are notable.[12 ]
Overall, Latin American countries have improved the amount of investments in healthcare
in the past two decades (7.3% of the gross domestic product in 2014 vs. 6.3% in 1995),
but still below the average of the Organization for Economic Co-operation and Development
(12.3%).[12 ] Also, different systems of health coverage coexist in many countries, ranging from
private to public models. As a consequence, healthcare access, development, and incorporation
of new technologies are heterogeneous between different countries and also across
different regions in the same country. The epidemiology of HCC in Latin America mirrors
important aspects of the healthcare organization and may be an indicator of defective
points such as screening coverage, early identification of at-risk populations, primary
prevention, early diagnosis, and expansion of access to proper treatment.
HCC Incidence and Mortality in Latin America
HCC Incidence and Mortality in Latin America
In 2018, there were around 840,000 cases of liver cancer, of which 4.6% (representing
around 38,400 cases) occurred in Latin America. Data from GLOBOCAN 2018 point out
an age-standardized incidence rate in different Latin American countries (considering
both sex and age) that ranges from less than 2.9 to more than 6.6 cases per 100,000.
According to region and sex, in Central America the male/female incidence is 6.7/6.0
per 100,000; in South America, it is 5.8/3.5 per 100,000; and North America (Mexico)
presents 10.1/3.4 per 100,000.[5 ]
In terms of global mortality, there were an estimated 762,000 deaths due to liver
cancer in 2018. The proportion of cases in Latin America is 4.7% (representing around
36,000 cases). The mortality in different countries ranges from less than 2.8 to more
than 6.3 per 100,000 ([Fig. 1 ]).[5 ] In accordance with what is observed in other parts of the world, the ratio between
incidence and mortality is close to 1, confirming the high lethality of liver cancer
in the region ([Table 1 ]).
Table 1
Estimated number of new cases and deaths due to liver cancer in 2018 (both sexes and
all ages)
Regions
New cases
ASR (world)
Deaths
ASR (world)
Latin America and the Caribbean
38,400
5.0
36,436
4.7
Asia
609,596
11.4
566,269
10.5
Europe
82,466
5.1
77,375
4.4
Africa
69,779
8.4
63,562
8.3
North America
41,851
6.6
34,339
4.8
Oceania
3,988
6.9
3,650
5.8
Abbreviation: ASR, age-standardized rates per 100,000.
Note: Data are from the International Agency for Research on Cancer (accessed August
14, 2019).
Fig. 1 Epidemiology of liver cancer in Latin America. Data are from the International Agency
for Research on Cancer (https://gco.iarc.fr/today/home , accessed August 15, 2019). (A ) Estimated age-standardized incidence rates in 2018; (B ) estimated age-standardized mortality rates in 2018; (c ) estimated number of prevalent cases (1 year) as a proportion in 2018. (ASR: age-standardized
rate per 100,000 population).
There is a paucity of data regarding HCC survival and long-term follow-up in Latin
America. However, reports are consistent with a high proportion of advanced stage
at diagnosis (20–41%), a significant rate of symptomatic disease at first presentation
(around 50%), and a better survival in patients under screening treated with curative
intent (around 30% at 5 years).[13 ]
[14 ]
[15 ]
Burden of Risk Factors for HCC in Latin America
Burden of Risk Factors for HCC in Latin America
Cirrhosis is the main risk factor for HCC regardless of the underlying etiology. It
is estimated that one-third of patients with cirrhosis will develop HCC during their
lifetime.[16 ]
The BRIDGE study, which was a multiregional longitudinal study that aimed to report
the real-life management of more than 18,000 HCC patients, showed that the most common
risk factor in all areas is HCV infection, except in China, South Korea, and Taiwan
where HBV was the predominant etiology.[17 ] This study did not report data from Latin America. Indeed, there is a paucity of
comprehensive information regarding demographic characteristics and occurrence of
risk factors in this region.
In 2017, Debes et al[15 ] reported a multinational cohort study involving 14 medical centers of six different
countries from South America, which aimed to identify the demographic features and
risk factors associated with HCC. This study included 1,336 patients between 2005
and 2015. Brazil accounted for 40% of the cohort (n = 540), followed by Argentina (19%; n = 251), Colombia (18%; n = 239), Peru (16%; n = 220), Ecuador (5%, n = 65), and Uruguay (2%, n = 21). The majority of patients were male (68%) and the median age was 64 years.
HCV infection was the most frequent risk factor, representing 48% of the cases. Alcoholic
cirrhosis was the second leading cause with 22%, followed by HBV infection in 14%,
NAFLD in 9%, and other causes in 8% (cryptogenic cirrhosis, hemochromatosis, autoimmune
liver disease, HBV/HCV coinfection, schistosomiasis, and primary biliary cirrhosis).
Besides, alcohol intake was associated with 29% of HCV and with 18% of HBV-related
cases.
In all countries, HCV and alcohol abuse were the main common risk factors. The only
exception was Peru. In this country, HBV was the leading cause, comprising 34% of
cases. In fact, the majority of the HCC cases related to HBV infection in Latin America
are reported from Peru and Brazil (34 and 38%, respectively), followed by Argentina
(16%), Colombia (7%), Ecuador (7%), and Uruguay (2%). Almost half of HBV-associated
cases in Peru were from the Amazonian region,[18 ] which comprehends a large area of Northwest Brazil, Peru, Venezuela, Colombia, and
Ecuador. HBV genotype F is the most prevalent in Amerindian population[19 ] and also in countries from Central[20 ] and South America[21 ] that cover the Amazonian region. This genotype is reported to be associated with
early onset of HCC in Alaska natives.[21 ] Notably, 38% of the HCC patients with HBV in Latin America were diagnosed before
the age of 50 years with a median age of 58 years. In patients with HCV, 94% were
diagnosed after age 50 years, with a median age of 63 years. NAFLD patients were diagnosed
with a median age of 67 years, and among patients with alcoholic cirrhosis, the median
age at diagnosis was 68 years.[15 ]
In a national Brazilian survey including 29 centers and 1,405 patients between 2004
and 2009, HCV infection was the main etiology (54%). HBV was found in 16% and alcohol
in 14%. Among HBV cases, 14.5% were associated with HCV coinfection and 3.4% with
hepatitis delta virus. Distinct prevalences of HCC were observed across different
Brazilian regions, probably due to differing prevalence of HBV (higher in Amazonian
region).[22 ] In 1997, another survey had showed that HBV was the most common cause of liver disease
in patients with HCC at that time in Brazil.[23 ] This suggests temporal changes in the distribution of risk factors over the past
two decades. Similar changes are also observed in global data: the proportion of HCV
increased from 37.1 to 40.1% between 1990 and 2016 in Western Europe, while alcohol
consumption decreased from 39.3 to 34.5% during the same period.[2 ]
The incidence of HCV-related HCC is expected to decrease due to the incorporation
of DAAs.[24 ] In Latin America, a prospective multinational cohort that followed 1,400 patients
treated with DAA reported an incidence of de novo HCC of 2% at 12 months and 4% at
24 months. In this cohort, most of the patients presented F3 or F4 fibrosis and around
28% had clinically significant portal hypertension. Achieving sustained virologic
response resulted in a relative HCC risk reduction of 73%, while failure to achieve
it was independently associated with de novo HCC. However, patients with F4 fibrosis
showed a cumulative incidence of 3 and 6% at 12 and 24 months, which suggests that
advanced liver disease demands continuous surveillance even in cases with sustained
virologic response.[25 ]
Conflicting information regarding the impact of DAA regimens on the occurrence of
de novo HCC are being published in other parts of the world.[8 ]
[26 ] In this regards, Latin American initiatives, as mentioned earlier, are crucial in
gathering evidence to future research on this topic.
In sum, the available evidence supports that the current scenario in Latin America
is similar to what is observed in the United States, Western Europe, and Japan regarding
the predominance of HCV and alcohol intake as the main etiologies. However, some regional
peculiarities are remarkable, as exemplified by the occurrence of HBV-related HCC
in Peru.
NAFLD/NASH: Current Trends Worldwide and in Latin America
NAFLD/NASH: Current Trends Worldwide and in Latin America
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) are recognized
as important causes of liver disease and HCC. In the United States, around 6 million
people have NASH and it represents a leading indication for liver transplantation.[27 ] About 10 to 30% of NAFLD cases may progress to cirrhosis, and HCC might appear even
in the absence of significant liver fibrosis in these patients.[28 ] Another relevant issue in this context is the likely overlap with alcohol, and there
is a need to better clarify the coexistence of alcohol and fatty liver disease in
some settings.
Patients with NASH seem to present a lower risk of HCC than patients with HCV-related
liver disease. In a large cohort study with NASH patients in the United States, the
incidence of HCC was 1.06 per 100 person-years.[29 ] NAFLD probably carries a lower risk of liver cancer than patients with NASH cirrhosis,
but because NAFLD affects a huge number of people around the world, this condition
is a relevant factor. Patients with noncirrhotic NAFLD have an incidence of HCC of
0.008 per 100 person-years.[29 ]
The impact of NAFLD/NASH on HCC epidemiology is likely to be underestimated due to
heterogenous definitions, differing proportions of patients with metabolic syndrome,
and referral bias.[30 ] Other adjuvant features of metabolic syndrome, such as diabetes and obesity, are
also considered emergent risk factors for HCC.
In Latin America, obesity and overweight have become major challenges. Around 57%
of the adult population (54% of men and 70% of women) is overweight and 19% (14.6%
of men and 24% of women) is obese. The highest prevalence of obesity is found in El
Salvador (33.0%) and Paraguay (30.1%) for women, and Uruguay (23.3%) and Chile (22.0%)
for men.[31 ] Additionally, NAFLD is highly prevalent in South America (31%), comparing to an
estimation of 25% in the adult population globally.[32 ]
In 2016, a Brazilian study aimed to evaluate clinical characteristics of patients
with HCC and NASH included 110 patients. In this cohort, obesity was observed in 52.7%
of cases, diabetes in 73.6%, dyslipidemia in 41.0%, and metabolic syndrome in 57.2%.
Fifty-two (47.2%) patients had histological diagnosis of HCC. Among those 52 patients,
NASH with cirrhosis was found in 32 (61.5%), NASH with fibrosis grades 1 to 3 in 14
(27%), and NASH without fibrosis in 2 (3.8%) patients. In four (7.7%) patients, HCC
was the only histological diagnosis, with a clinical diagnosis of NAFLD.[33 ]
A longitudinal cohort from Argentina included 708 HCC patients diagnosed between 2009
and 2015 and showed that NAFLD was the third cause of HCC, representing 11.4% of the
cases (the first was HCV in 37%, followed by alcoholic liver disease in 20.8%). During
the study period, there was a sixfold increase in the incidence of NAFLD-related HCC,
with 4.3% of NAFLD-related HCC in 2009 and 25.6% in 2015.[34 ]
In the same sense, a study involving two hospitals from Chile with 288 patients with
HCC reported an increase in NAFLD and a decrease in alcoholic liver disease. Notably,
the leading cause of liver disease in this cohort was NAFLD (38.8%), followed by HCV
(25.2%).[35 ]
Unpublished data from Brazilian registries of 508 liver transplantations in Hospital
das Clínicas da Faculdade de Medicina da Universidade de São Paulo reported an increase
in the proportion of NASH as the etiology of liver disease in patients submitted to
liver transplantation. Between 2007 and 2009, 4 (0.5%) were attributed to NASH and
between 2016 and 2018, there were 25 cases (3.2%). However, surgical series may overestimate
the occurrence of HCC in noncirrhotic NASH liver, as these patients are more likely
to be considered for resection than patients with the same tumor burden but with poor
liver function. Besides, NASH requires histological confirmation. This is an important
consideration when analyzing epidemiological data on this topic.
To sum up, there is a global concern regarding a potential increasing in the number
of patients with NAFLD- and NASH-related HCC. This is particularly important in Latin
America, given that NAFLD is highly prevalent in this region. Up till now, there is
no strong data from the region supporting that NAFLD/NASH is a leading cause of HCC.
However, the initial reports mentioned in this section warrant continued exploration
and data collection, with detailed risk factor exposure and histological evaluation.
Importantly, alcohol intake in studied populations should be registered to rule out
a biased conclusion.
Regional Particularities: Early Onset of HBV-Related HCC and Molecular Profile of
Aflatoxin-Related HCC
Regional Particularities: Early Onset of HBV-Related HCC and Molecular Profile of
Aflatoxin-Related HCC
Despite the fact that the general context of HCC in Latin America shares similarities
with many Western countries, some groups have described patterns of HCC occurrence
with specific characteristics in different Latin American regions.
This is the case for an unusual form of HCC affecting children, adolescents, and young
adults described in a retrospective series of 232 HCC patients submitted to surgical
resection in Peru between 1990 and 2006. The median age of this cohort was 36 years,
and 44.2% were associated with chronic HBV infection (not including those with resolved
infection: HBsAg negative and anti-HBc positive). Only 16.3% of them had cirrhosis
and the median AFP level was 5,467 ng/mL.[36 ] This lower incidence of cirrhosis, when comparing to data from other Western regions,[37 ] probably relies on the early onset and the etiologic background, with a predominance
of HBV and only 5% related to HCV infection.[36 ] Another study in the Peruvian population with 1,541 patients described a bimodal
incidence of HCC, with a first peak of incidence around the age of 25 years and a
second one at the age of 64 years.[38 ]
The retrospective nature of the data prevents any definitive conclusion and selection
bias may affect interpretation. However, this result suggests a particular behavior
in terms of clinical course and an unusual HCC population, mirroring data from sub-Saharan
Africa and Taiwan with HBV infection during birth or immediately after.[39 ]
To analyze whether genetic variations exist between younger and older HCC patients,
Marchio et al[40 ] performed a study involving 80 Peruvian patients, 41 diagnosed under 40 years old,
and 39 diagnosed over 40 years old. Mutations in the Wnt pathway were more frequent among younger patients compared with patients older than
40 years and AXIN1 mutations were more frequent in women than in men. The authors also described a predominance
of genetic alterations represented by insertions/deletion.
In a subsequent analysis, another molecular study including 65 Peruvian patients was
conducted. The authors found HBV DNA in the tumor and/or matched nontumor tissue in
81.5%, predominantly among younger patients. Besides, a low viral HBV DNA burden among
younger patients was also found, which challenges the hypothesis that associates high
HBV DNA load with earlier tumor development.[41 ]
Although these findings were not validated in other Latin American cohorts, they suggest
that key aspects in the hepatocarcinogenesis might be different to that observed in
other parts of the world. In this regard, additional studies are required to support
the implementation of strategies on prevention (mainly expanding HBV vaccination in
Amazonian region), diagnosis, and treatment for HCC patients who share these molecular
features.[41 ]
Latin America compromises 3% of the global burden of aflatoxin-related HCC.[42 ] Aflatoxins are produced by the fungi Aspergillus parasiticus and Aspergillus flavus , which colonize food commodities such as groundnuts and tree nuts in tropical regions
of the world. Aflatoxin exposure in food is a well-documented risk factor for HCC,
presenting most often in individuals with chronic HBV infection, with up to 30 times
greater risk than aflatoxin exposure without HBV.[43 ]
[44 ] Aflatoxin exposure predominantly affects rural populations more than urbanized populations.[45 ]
Liu et al[42 ] conducted a quantitative cancer risk assessment that approached aflatoxin exposure
and HBV prevalence to estimate the global burden of aflatoxin-related HCC. The estimation
in Latin America is 6.0 to 15.0 and 0.20 to 0.50 aflatoxin-induced HCC cases per year
per 100,000 people in HBsAg-positive and HBsAg-negative patients, respectively. This
estimation was based only on data from Brazil, Mexico, and Argentina; therefore, it
is not fully representative of the entire Latin America. This indicates a higher incidence
compared with North America (0.08–0.3 and 0.003–0.01 per 100,000) and Europe (0–1.2
and 0–0.04 per 100,000), but with a better general outlook compared with Africa (3.0–54.0
and 0.1–1.8 per 100,000) and Southeast Asia (9.0–30.0 and 0.30–1.00 per 100,000).
Nogueira et al[46 ] assessed the frequency of TP53 249Ser mutation in 74 HCC patients submitted to resection
or transplantation in a Brazilian cohort. This mutation is a molecular evidence of
aflatoxin-related carcinogenesis and there is a strong correlation between this mutation
and dietary exposure of aflatoxin. In this study, the 249-Ser mutation was found in
28% of cases, suggesting that aflatoxin is a potential risk factor in the studied
population. Moreover, this mutation was correlated with larger tumors and poorly differentiated
histology.
Screening for HCC in Latin America
Screening for HCC in Latin America
Screening is widely applied, although evidence of positive impact on reducing mortality
is scarce. A randomized controlled trial that supports screening for HCC was performed
in China with more than 18,000 patients and demonstrated a 37% reduction in risk of
death in screened patients with abdominal ultrasound and α-fetoprotein (AFP) test
performed every 6 months.[47 ] However, this study included only the HBV-infected population, study adherence was
poor, and the trial is limited by the use of randomization by clusters.
A validation trial in other parts of the world, such as the United States, Europe,
or Latin America is unfeasible, and its implementation would be ethically questionable.
Therefore, ultrasonography every 6 months is a part of the routine evaluation of patients
with chronic liver disease and high risk of HCC, and this practice is endorsed by
the current clinical guidelines.[48 ] The role of AFP as a surveillance tool is not well defined, mainly because varying
levels of AFP levels might reflect activity of the underlying liver disease[49 ] and also because only a small proportion of early-stage tumors show elevated AFP
levels.[50 ] Abdominal ultrasound has several advantages including low cost, easy availability,
and safety. These features enable ultrasound to be applicable in regions with different
socioeconomic contexts.
The implementation of surveillance programs with a significant rate of early detection
was reported in a prospective Brazilian study with 884 cirrhotic patients. Paranaguá-Vezozzo
et al[51 ] characterized a long-term follow-up of patients who were submitted to at least one
annual liver ultrasonography and a serum AFP measurement. During the study period
(1998–2008), 72 (8.1%) patients developed HCC with an annual incidence of 2.9%. Of
these 72 patients, around 80% were diagnosed with early stage, which allowed curative-intended
treatments in the majority of the cases.
In a Latin American multinational retrospective study of incident HCC cases, there
were significant differences in the proportion of patients diagnosed in each of the
Barcelona Clinic Liver Cancer (BCLC) stages between patients who were enrolled in
screening programs (n = 102) and those with incidental diagnosis (n = 86). In the former, 69.6% were diagnosed with BCLC-A stage, while in the latter,
only 39.5% were BCLC-A. Consequently, more patients had BCLC-C and -D in the nonscreened
group (18.6 vs. 8.0%).[52 ] Another cohort corroborated that individuals who attended ultrasound surveillance
with a frequency of at least every 6 months had a higher probability of being diagnosed
with early-stage tumors.[53 ]
In terms of ultrasonography accuracy for HCC detection, a study performed in Argentina
included 643 cirrhotic patients on liver transplantation waiting-list. In this study,
the sensitivity was 33% and specificity was 99%.[54 ] These results are in line with a recent meta-analysis that showed a sensitivity
of 45% for detection of early HCC with a specificity of 84%.[55 ]
There is no large study analyzing the coverage of ultrasound screening for early detection
of HCC, mainly in remote areas of Latin America. The proportion of patients diagnosed
with an incidental HCC outside a structured surveillance program is over 50%[15 ] and it is probably higher in unreported areas. Most of the data available come from
academic institutions, in which patient care and adherence tend to be broader ([Table 2 ]). As a consequence, there is likely to be an insufficient coverage and a significant
rate of underreported advanced stage at initial presentation.
Table 2
Studies from Latin America approaching risk factors and/or screening coverage
Population
Period
Risk factors
Methodology
Diagnosis under screening
Debes et al[15 ]
N = 1,336
Brazil, Argentina, Colombia, Ecuador, Peru, and Uruguay
2005–2015
HCV: 48%
HBV: 22%
Alcohol: 14%
NAFLD/NASH: 9%
Retrospective multicentric study
47% diagnosed during screening
Bertani el al[38 ]
N = 1,541
Peru
1997–2010
HCV: 4.7%
HBV: 50.1%
HCV + HBV: 1.4%
Retrospective multicentric study
Not reported
Carrilho et al[22 ]
N = 1,405
Brazil
2004–2009
HCV: 54%
HBV: 16%
Alcohol: 14%
NASH/NAFLD: 3%
Retrospective multicentric study
Not reported
Fassio et al[52 ]
N = 240
Brazil, Argentina, Colombia, Chile, Uruguay, and Venezuela
2007–2009
HCV: 30.8% Alcohol: 20.4%
HBV: 10.8%
HCV + alcohol: 5.8%
Prospective multicentric study
54% diagnosed during surveillance
Kikuchi et al[13 ]
N = 364
Brazil
2010–2012
HCV: 55%
HBV: 13%
Alcohol: 16%
NASH: 9%
Retrospective multicentric study
65% diagnosed during screening
Piñero et al[14 ]
N = 708
Argentina
2009–2016
HCV: 37%
Alcohol: 20.8%
NASH/NAFLD: 11.4%
HBV: 5.4%
Multicentric study
58.1% diagnosed during screening
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis
C virus; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.
Adherence to Clinical Practice Guidelines in Latin America: from Diagnosis to Treatment
Adherence to Clinical Practice Guidelines in Latin America: from Diagnosis to Treatment
Adherence to guidelines is hampered by the heterogeneity in available resources, the
unequal structure of healthcare systems, and imbalances in the geographical distribution
of reference centers with expertise in HCC. The reality in these centers is further
discussed in this section, but this may not be representative of the whole picture
of Latin America.
Regarding diagnostic procedures, noninvasive imaging diagnosis of HCC in patients
with cirrhosis and typical radiological hallmarks are accepted since 2001[56 ] and endorsed by clinical practice guidelines.[48 ]
[57 ] Both computed tomography and magnetic resonance have a good accuracy in detecting
HCC according to the noninvasive diagnostic criteria,[48 ]
[57 ] although false-positive findings are described. A multinational Latin American study
with 422 HCC patients submitted to liver transplantation reported that only 18 patients
did not had confirmed HCC in the explanted liver, showing a low rate of disparity
between radiologic and histologic findings.[58 ]
Improvement in diagnostic accuracy, especially in the detection of small and potentially
curable lesions, is under active debate worldwide.[59 ] The use of Li-RADS criteria integrates features not related to tumor enhancement,
such as capsule and growth over time. This adds more complexity in clinical decision
making, particularly in intermediate categories (Li-RADS 3 and 4), which can represent
a potential source of misinterpretation of the system and low adherence to treatment
algorithms worldwide.
Several staging systems have been designed to provide prognostic information and help
clinical decision. The BCLC staging system[6 ] is endorsed by practical guidelines, including the Latin America Association for
the Study of the Liver.[60 ] This classification has been externally validated in different clinical settings
and is frequently updated to incorporate the ongoing novelties and concepts.[61 ]
[62 ]
The BRIDGE study[17 ] documented marked heterogeneity of treatment approaches across different regions
and countries. Accordingly, regional differences, access, and costs may lead to a
similar context in Latin America. Transarterial chemoembolization was the most frequent
used and transplantation was the less used modality in a multicenter South American
cohort, while ablation, resection, and systemic therapy varied among countries.
The adherence to the BCLC system varies from 49 to 71% in different publications.[63 ]
[64 ] A multicenter study performed by Piñero et al[14 ] in Argentina, involving 14 hospitals and 708 patients, evaluated the adherence to
the BCLC system. The overall adherence was 53% and the lowest adherence was reported
in BCLC-C patients (29.8%).
Accordingly, a Brazilian retrospective study also reported an adherence to the BCLC
staging system of 52% in 364 patients between 2010 and 2012. The rate of adherence
varied in different stages: BCLC-0, 33%; BCLC-A, 45%; BCLC-B, 78%; BCLC-C, 35%; and
BCLC-D, 67%. In early and very early stages, adherence impacted positively on overall
survival and no differences were observed between adherent and nonadherent patients
in BCLC-B and C stages.[13 ]
The selection of patients for liver transplantation is key to improve outcomes in
the subset of patients with liver-only disease. Unfortunately, lack of access and
disparities in health coverage are barriers in the development of liver transplantation
programs in Latin America. While some countries, such as Argentina, Brazil, Colombia,
Peru, Mexico, and Chile, dispose of consolidated programs, lower middle-income countries,
such as Honduras, Nicaragua, and Guatemala, are not able to maintain liver transplantation
programs.[65 ] Even the countries with a large number of liver transplantations face difficulties
regarding intraregional disparity and geographic distances. The need for a more structure
health system and international cooperation are crucial in Latin America, together
with initiatives to educate the population and increase awareness of organ donation
in the regions with well-established transplantation activity.
This scenario will probably become more challenging, as new DAA therapy is shown to
reduce the indications for liver transplantation due to HCV[66 ] and less strict criteria (beyond Milan) are being studied to expand the indication
in HCC patients.
According to data from Latin American countries with established transplantation programs,
HCC accounts for 11 to 17% of the liver transplantations in the region.[67 ]
[68 ]
[69 ] Milan criteria are the most frequent use and around 75 to 90% of the reported cohorts
are in these criteria.[67 ]
[68 ]
[69 ]
[70 ] The posttransplantation recurrence rate in a large Brazilian[71 ] cohort was 8%, similar to what is described in the literature worldwide.[72 ]
Systemic therapies are recommended for BCLC-C patients or those who progressed on
or have contraindications to locoregional modalities. The first agent that improved
survival in this group was sorafenib. This drug was incorporated in the clinical practice
worldwide in 2008, after the publication of two pivotal trials.[73 ]
[74 ] Although costs are an important issue, sorafenib is currently adopted in many Latin
American countries. In a multicenter study with sorafenib-treated patients from Argentina,
Brazil, Colombia, Ecuador, and Peru, 80% received sorafenib as the upfront treatment
once most of the patients had BCLC-B and C stages. The median survival of this cohort
was 8 months,[75 ] inferior to what was observed in the SHARP trial.[73 ] Low survival in patients under systemic treatment with sorafenib was also observed
in other Latin American cohorts.[76 ]
[77 ] Socioeconomic differences, delay in starting treatment, administrative and organizational
deficiencies, and inclusion of subgroups of patients with no strong evidence (for
example, liver dysfunction and BCLC-D stage) are possible reasons for the poor survival.
In 2017, a second-line agent, regorafenib, was approved based on positive results
of a phase III trial.[78 ] This agent received local approval in Latin American countries such as in Brazil,
Colombia, Argentina, and Mexico, but is not yet widely included in the daily practice
in public health. In the last 2 years, two additional agents (cabozantinib[79 ] and ramucirumab[80 ]) also demonstrated survival improvement in phase III studies. However, due to delays
in drug approval by local regulatory bodies, most Latin American countries still face
difficulties in offering novel drugs to HCC patients. Use of cytotoxic chemotherapy
(mainly doxorubicin and fluoropyrimidine combinations) was reported in patients after
sorafenib exposure with disappointing overall survival in a Brazilian experience.[81 ] This scenario highlights that better outcomes with systemic treatment in HCC require
integration of financial and organizational factors with the application of clinical
criteria grounded on the best evidence available.
Challenges and Future Perspectives
Challenges and Future Perspectives
In this review, we described the available data on HCC epidemiology in Latin America
comparing to global trends and the changing landscape in the management of this malignancy.
Globally, as well as in Latin America, HCC is a major health problem and one of the
leading causes of cancer mortality.
The familiarity with the prevalence of risk factors and how they may change in the
coming years should drive new programs directed to improve the rate of early-stage
diagnosis. HCV still represents the main etiology associated with HCC. Interferon-free
regimens for HCV provided high rates of cure; so, an effort to identify and treat
HCV patients will surely impact positively on the incidence of HCC. HBV vaccination
is an urgent need in some regions with high incidence. These actions should integrate
the general population, medical professionals, academic institutions, and government
agencies.
Strategies on how to screen patients with NAFLD/NASH is a matter of intense debate
and study worldwide. The current focus is placed on trying to identify which group
of patients with NAFLD/NASH without cirrhosis should be screened, and how the screening
should be performed.[30 ] As a region with a clear trend of increasing in NAFLD prevalence, Latin American
centers should contribute to generating evidence on this issue.
Research, training, and scientific exchange are a driver for health care improvement,
especially in the field of liver cancer. Medical education initiated in reference
centers and disseminated to the primary healthcare system is paramount to improve
primary prevention, implementation of comprehensive surveillance programs at high-risk
patients, and access to treatment options supported by the best available evidence.
Multinational initiatives and dedicated network groups between Latin American countries
and integrated with centers in other parts of the world can overcome the inherent
socioeconomic difficulties and provide better care to HCC patients.
Main Concepts and Learning Points
Main Concepts and Learning Points
Hepatocellular carcinoma is a major issue in Latin America. Improvements in health
care access, surveillance, and continuing medical training are required.
Increasing reports of liver cancer associated with fatty liver disease in Latin America
mirror a trend observed in many Western countries.
Viral hepatitis, alcohol, and aflatoxin remain predominant risk factors in Latin America.
Multinational network efforts integrated with referral groups worldwide are paramount
to delivering better care to hepatocellular carcinoma patients.
